ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
Clinical trials in the era of precision cancer medicine - for the few or for the many?
Acta Oncol, 59 (7), 731-732
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer